Cited by 145Sleep and related disordersObstructive Sleep Apnea ResearchCircadian rhythm and melatonin

Trimipramine in Primary Insomnia: Results of a Polysomnographic Double-Blind Controlled Study

Riemann, D., Voderholzer, U., Cohrs, S., Rodenbeck, A., Hajak, G., Rüther, E., Wiegand, M. H., Laakmann, G. +6 more·2002·Pharmacopsychiatry

Abstract

In recent years, sedating antidepressants have been increasingly used to treat primary insomnia. Up to now, only one open pilot study with trimipramine and one double-blind placebo-controlled study with doxepin have provided scientific support for this approach in treating primary insomnia. In order to test the hypothesis that sedating antidepressants are useful in the treatment of primary insomnia, the effect of trimipramine on objectively and subjectively measured parameters of sleep was investigated in a double-blind placebo- and lormetazepam-controlled study in a sample of 55 patients with primary insomnia attending outpatient sleep-disorder clinics. Trimipramine was selected since it has shown positive effects on sleep continuity with a lack of REM sleep suppression in studies on depressed patients and in one pilot study on patients with primary insomnia. Trimipramine at an average dose of 100 mg over a period of 4 weeks significantly enhanced sleep efficiency, but not total sleep time (which had been the primary target variable) compared to placebo as measured by polysomnography. Changes in objective sleep parameters were paralleled by changes in subjective sleep parameters. Trimipramine did not suppress REM sleep. Lormetazepam decreased wake time and sleep stage 3 and increased REM sleep compared to placebo. After switching trimipramine to placebo, sleep parameters returned to baseline. There was no evidence of any rebound effect from trimipramine. Side effects from tr…

Integrity signals

Registry

Crossref · 10.1055/s-2002-34119

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Evidence for efficacy of sedating low-dose antidepressants when used alone is relatively weak.

    “Evidence for their efficacy when used alone is relatively weak 38-42 and no specific agent within this group is recommended as preferable to the others in this group.”
  • Trimipramine (mean 100mg) was not associated with REM sleep suppression, when compared to placebo, in insomnia patients.

    “(Riemann et al., 2002) found that trimipramine (mean 100mg) was not associated with REM sleep suppression, when compared to placebo with insomnia patients.”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Riemann et al., 2002

  • REM sleep suppression is reported with all TCAs except trimipramine.

    “REM sleep suppression is reported with all TCAs except trimipramine (Riemann et al., 2002).”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Riemann et al., 2002

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Riemann, D., Voderholzer, U., Cohrs, S., Rodenbeck, A., Hajak, G., Rüther, E., Wiegand, M. H., Laakmann, G., Baghai, T., Fischer, W., Hoffmann, M., Hohagen, F., Mayer, G., & Berger, M.
Affiliations
  • University of Freiburg (DE)
  • University of Göttingen (DE)
  • Technical University of Munich (DE)
  • Ludwig-Maximilians-Universität München (DE)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • University of Lübeck (DE)
Venue
Pharmacopsychiatry
Published
2002-09
Volume
35
Issue
5
Pages
165-174
ISSN
  • 0176-3679 (ISSN-L)
  • 1439-0795
OpenAlex
W1987429320
Cited by
145
References
11
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 1 · 2019: 8 · 2018: 4 · 2017: 8 · 2016: 3 · 2015: 7 · 2014: 7 · 2013: 11 · 2012: 8
FWCI
7.68
Type
journal article
Language
en
Open access
closed
Locations
  • Pharmacopsychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
  • GRO (submittedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Physiology › Obstructive Sleep Apnea Research
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
Keywords
trimipramine, primary insomnia, sedating antidepressants, lormetazepam, sleep efficiency, REM sleep suppression, sleep continuity, rebound effect, antidepressant side effects
MeSH terms
Adult, Antidepressive Agents, Tricyclic, Benzodiazepines, Double-Blind Method, Female, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Lorazepam, Male, Middle Aged, Sleep Stages, Sleep, REM, Anti-Anxiety Agents, Trimipramine, Treatment Outcome, Polysomnography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review